Teva Pharma: Why This Generic Drug Giant Is a Smart Buy Now
Teva Pharmaceuticals Industries Ltd NYSE: TEVA is the world's largest generic drug maker, with over 500 generic and biosimilar treatments in its broad portfolio. The medical sector giant also has a line of branded drugs driving growth.
Teva Pharmaceutical: 2025 Guidance Sinks The Stock, But Presents An Opportunity
Teva Pharmaceutical Industries' Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. Management's cautious 2025 guidance sets a low bar, likely to be outperformed, and a desirable entry point for long-term investors. Teva Pharmaceutical's pipeline, including Duvakitug and multiple biosimilars, offers significant growth prospects, with several key Phase 3 milestones and potential launches from 2025 to 2027.
TEVA Stock Down 14% Despite Q4 Earnings & Revenues Beat Estimates
Teva stock falls 14% despite better-than-expected fourth-quarter earnings results due to a weak 2025 outlook.
Why Teva Pharmaceutical Stock Is Sinking Today
Shares of Teva Pharmaceutical Industries (TEVA -13.21%) were slipping Wednesday. The company's stock lost 13.5% as of 1:15 p.m.
Crude Oil Down 1.5%; Teva Pharmaceutical Shares Plummet
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling around 1% on Wednesday.
Teva Pharma CEO: Guidance based on the new Teva that grows every year
Richard Francis, Teva Pharmaceuticals CEO, joins 'Money Movers' to discuss the company's quarterly earnings results, drug price negotiations, and much more.
Teva Pharmaceutical Industries Limited (TEVA) Q4 2024 Earnings Conference Call Transcript
Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Q4 2024 Earnings Conference Call January 29, 2025 8:00 AM ET Company Participants Christopher Stevo - SVP, IR Richard Francis - President & CEO Eric Hughes - Head of R&D & Chief Medical Officer Eli Kalif - CFO Conference Call Participants Umer Raffat - Evercore ISI Jason Gerberry - Bank of America David Amsellem - Piper Sandler Balaji Prasad - Barclays Ash Verma - UBS Yifeng Liu - HSBC Glen Santangelo - Jefferies Chris Schulz - J.P. Morgan Operator Hello, and welcome to the Fourth Quarter and Full-Year 2024 Teva Pharmaceutical Industries Earnings Conference Call.
Teva Pharmaceutical Industries (TEVA) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Teva Pharmaceutical Industries (TEVA) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Teva Pharm Q4 tops estimates on strong sales of its own drugs
Teva Pharmaceutical Industries reported a slightly larger than expected rise in fourth-quarter profit, helped by double-digit sales gains in a trio of its branded drugs to treat migraines, Huntington's disease and schizophrenia.
Pharmaceutical Name Gearing Up for Earnings
Israel-based pharmaceutical giant Teva Pharmaceutical Industries Ltd (NYSE:TEVA) is preparing for its latest quarterly earnings report, due out before the open Wednesday, Jan. 29.
Teva Pharmaceutical Industries Limited (TEVA) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)
Teva Pharmaceutical Industries Limited (NYSE:TEVA ) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2025 11:15 AM ET Company Participants Richard Francis - President and CEO Eric Hughes - Head of R&D and Chief Medical Officer Conference Call Participants Chris Schott - J.P.
Teva Pharmaceuticals CEO talks Trump and US healthcare
Pharmaceutical companies brace for the upcoming Trump administration. Teva Pharmaceuticals (TEVA) CEO Richard Francis joins Seana Smith and Madison Mills on Catalysts to discuss what both the pharmaceutical company and industry at large are expecting from Trump's return to the White House.
